Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

Masanori Miwa, Masako Ura, M Nishida et al. · European Journal of Cancer · 1998 · 1.2K citations

Medicine, Oncology, Pharmacology +12

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study

Christos Kosmas, Manolis S. Kallistratos, Petros Kopterides et al. · Journal of Cancer Research and Clinical Oncology · 2007 · 334 citations · Full text

Medicine, Cardiology, Pharmacology +14

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

Søren Astrup Jensen, Jens Benn Sørensen · Cancer Chemotherapy and Pharmacology · 2006 · 232 citations

Medicine, Pharmacology, Pharmacotherapy +12

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.

Shereif H. Rezkalla, Robert A. Kloner, John F. Ensley et al. · Journal of Clinical Oncology · 1989 · 188 citations

Medicine, Oncology, Pharmacology +13

5-Fluorouracil induces arterial vasocontractions

T Südhoff, M. Enderle, Michaela Pahlke et al. · Annals of Oncology · 2004 · 165 citations

Medicine, Pharmacology, Pharmacotherapy +10